Good article. Borderline ovarian tumors (BOTs) were first described as a separate group in 1929 by Taylor [1] , but only in 1973, they were accepted by the International Federation of gynecology and Obstetrics (FIGO) as carcinomas of low malignant potential [2] and from 1973 by the World Health Organization (WHO) as ‘borderline ovarian tumors’ [3] , the... Continue Reading →
On mourning a “loss of fertility” v’s celebrating good health
This is what I wrote in an on-line discussion today about “loss of fertility” among young(er) women with BOT. Am I wrong to want to celebrate my health rather than mourn my “loss of fertility”? ….. it’s a really personal decision and one that - due to our own personal feelings, beliefs, circumstances and thoughts... Continue Reading →
A great website and resource but I do find it frustrating that a BOT is referred to as a cancer.Interview with a borderline ovarian tumour patient
Interview with a borderline ovarian tumour patient
Borderline ovarian tumour is a useful and helpful terminology that should be retained. Presence of a micropapillary pattern is not associated with a more aggressive tumour/worse outcome. W Glenn McCluggage DIAGNOSTIC HISTOPATHOLOGY 20:9 2014 Abstract Ovarian borderline tumours are relatively uncommon but not rare neoplasms. A large majority are of serous or mucinous type with other morphological... Continue Reading →
Ovarian borderline tumours: a review with comparison of serous and mucinous types (and more on the naming game, and on micropapillary pattern)
“At the moment, the way we assess women with ovarian cysts for the presence of cancer and select treatment lacks accuracy. This new approach to classifying ovarian tumours can help doctors make the right management decisions, which will improve the outcome for women with cancer. It will also reduce the likelihood of women with all... Continue Reading →
New test can help doctors choose best treatment for ovarian cancer
Exciting new model to assist in diagnosis of benign, borderline and cancerous ovarian tumours.Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study | The BMJ
Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study | The BMJ
M(ucinous)BOTs == S(erous)BOTs
In the present series of BOT (borderline ovarian tumour) with the largest number of patients treated conservatively to date, the presence of a MPP (micropapillary pattern) and the mucinous subtype were associated with a higher rate of progression to carcinoma after conservative management. These important results suggest that MBOT (mucinous BOT) belong to a ‘high-risk’... Continue Reading →
The overall outcome of SBTs is very favorable. The 5-year survival rates for patients with disease that is stages I–IIIb are between 88% and >95% [18]. For patients with stage I tumors, the risk of recurrence or the development of a second SBT has been estimated to be only 5%–10% [7, 8, 14]. Other than... Continue Reading →
More on The Naming Game
Although the term ‘borderline’ may suggest uncertainty, it accurately describes the ambiguous histologic and biologic features of these neoplasms and remains the most appropriate term. Accordingly, it has been recommended by the World Health Organization (WHO) for the last four decades [2]. The majority of these tumors are associated with a favorable prognosis and the... Continue Reading →
Age-dependent differences in borderline ovarian tumours (BOT) regarding clinical characteristics and outcome
Annals of Oncology 25: 1320–1327, 2014 doi:10.1093/annonc/mdu119 Published online 11 March 2014 Borderline ovarian tumours (BOT) represent a distinct tumour entity of epithelial origin accounting for approximately 10%–20% of all ovarian neoplasms [1, 2]. In contrast to ovarian cancer, they are characterised by the absence of destructive stromal invasion. They are distinct by an epidemiological shift towards younger women and an excellent overall prognosis with a 5-year survival rate of more than 90% across all tumour stages [3–5]. Nevertheless, BOT may recur even after more than 10 years and undergo malignant transformation in selected cases [6].... Continue Reading →
jozi-ovari 